Despite FDA Setback, MEI’s Zandelisib Could Still Break PI3K Curse
Drug Faces Longer Path To Market
MEI/Kyowa Kirin will no longer seek accelerated approval based on a single-arm study as the FDA is calling for Phase III data due to growing conservatism regarding the PI3K class.
